BioTek congratulates Dr. Jeff Peterson of the Fox Chase Cancer Center in Pennsylvania for winning a new Cytation™ 3 Cell Imaging Multi-Mode Reader in BioTek's "Think Possible" Application Contest.
Entrants were judged on a short essay that they submitted, detailing the application that they think is possible for their specific research using the Cytation 3. As an Associate Professor, Dr. Peterson studies chemical biology and kinase signaling in cancer.
"Multiplexing of disparate assays using multiple detection modalities is the future," Dr. Peterson wrote as part of his essay. "Cytation 3 is the first instrument that I am aware of that bridges the gap between imaging-based phenotypic screening and targeted assays using biochemical readouts. When both approaches are feasible simultaneously, the debate between phenotypic and targeted screening approaches dissolves to reveal a new world of possibilities."
As Dr. Peterson noted in his essay, patent pending Cytation 3 provides both quantitative and phenotypic cellular analyses by combining automated digital fluorescence microscopy and conventional microplate detection in a single platform.
Multi-channel widefield fluorescence and brightfield imaging are supported using high-intensity LED light sources and onboard filter cubes, and automated functions allow increased throughput compared to manual microscopy systems.
Hybrid Technology™ multi-mode detection combines high sensitivity filter-based detection and flexible monochromator-based detection for unmatched assay versatility now and in the future. This modular, parallel data acquisition platform allows scientists to collect more meaningful data, increase sample throughput, and reduce experimental time.
Cytation 3 is the recipient of three awards since its launch: the MipTec New Product Innovation Award, the SelectScience "Scientists' Choice Award for Best Drug Discovery Product" Award, and Thermo Fisher Scientific "Extraordinary New Product Line Award". It is also a finalist in the 2014 Edison Awards® competition.